Valentin S Schäfer1,2, Stavros Chrysidis3,4, Christian Dejaco3,4, Christina Duftner3,4, Annamaria Iagnocco3,4, George A Bruyn3,4, Greta Carrara3,4, Maria Antonietta D'Agostino3,4, Eugenio De Miguel3,4, Andreas P Diamantopoulos3,4, Ulrich Fredberg3,4, Wolfgang Hartung3,4, Alojzija Hocevar3,4, Aaron Juche3,4, Tanaz A Kermani3,4, Matthew J Koster3,4, Tove Lorenzen3,4, Pierluigi Macchioni3,4, Marcin Milchert3,4, Uffe Møller Døhn3,4, Chetan Mukhtyar3,4, Cristina Ponte3,4, Sofia Ramiro3,4, Carlo A Scirè3,4, Lene Terslev3,4, Kenneth J Warrington3,4, Bhaskar Dasgupta3,4, Wolfgang A Schmidt3,4. 1. From the University Hospital Bonn III, Medical Clinic, Department of Oncology, Hematology and Rheumatology, Bonn; Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch, Berlin; Asklepios Medical Center, Bad Abbach, Germany; Hospital of Southwest Denmark, Esbjerg; Diagnostic Centre Region Hospital Silkeborg, Silkeborg; Odense University Hospital, Odense; Copenhagen Center for Arthritis Research (COPECARE), Glostrup, Denmark; Medical University Graz, Graz; Medical University Innsbruck, Innsbruck, Austria; Hospital of Bruneck, Bruneck; Università degli Studi di Torino, Turin; Epidemiology Unit - Italian Society for Rheumatology (SIR), Milan; Arcispedale Santa Maria Nuova, Reggio Emilia; University of Ferrara, Italy; MC Groep Hospitals, Lelystad; Leiden University Medical Center, the Netherlands; Hôpital Ambroise Paré, Boulogne-Billancourt, France; University Hospital La Paz, Madrid, Spain; Martina Hansens Hospital, Bærum, Oslo, Norway; University Medical Centre Ljubljana, Ljubljana, Slovenia; University of California at Los Angeles, Los Angeles, California; Mayo Clinic, Rochester, Minnesota, USA; Pomeranian Medical University, Szczecin, Poland; Norfolk and Norwich University Hospital, Norwich; Southend University Hospital, UK National Health Service (NHS) Foundation Trust and Anglia Ruskin University, Westcliff, UK; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon; Rheumatology Department, Hospital de Santa Maria - CHLN, Lisbon, Portugal. valentin.s.schaefer@hotmail.de. 2. V.S. Schäfer, MD, University Hospital Bonn III, Medical Clinic, Department of Oncology, Hematology and Rheumatology, and Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch; S. Chrysidis, MD, Hospital of Southwest Denmark; C. Dejaco, MD, PhD, Medical University Graz, and Hospital of Bruneck; C. Duftner, MD, PhD, Medical University Innsbruck; A. Iagnocco, MD, Università degli Studi di Torino; G.A. Bruyn, MD, PhD, MC Groep Hospitals; G. Carrara, MSc, Epidemiology Unit - SIR; M.A. D'Agostino, MD, PhD, Hôpital Ambroise Paré; E. De Miguel, MD, University Hospital La Paz; A.P. Diamantopoulos, MD, PhD, MPH, Martina Hansens Hospital; U. Fredberg, MD, PhD, Diagnostic Centre Region Hospital Silkeborg, and Odense University Hospital; W. Hartung, MD, Asklepios Medical Center; A. Hocevar, MD, MSc, University Medical Centre Ljubljana; A. Juche, MD, Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch; T.A. Kermani, MD, University of California at Los Angeles; M.J. Koster, MD, Mayo Clinic; T. Lorenzen, MD, Diagnostic Centre Region Hospital Silkeborg; P. Macchioni, MD, Arcispedale Santa Maria Nuova; M. Milchert, MD, PhD, Pomeranian Medical University; U.M. Døhn, MD, PhD, COPECARE; C. Mukhtyar, MBBS, MSc, MD, Norfolk and Norwich University Hospital; C. Ponte, MD, Rheumatology Research Unit, Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, and Rheumatology Department, Hospital de Santa Maria - CHLN; S. Ramiro, MD, MSc, PhD, Leiden University Medical Center; C.A. Scirè, MD, PhD, Epidemiology Unit - SIR, and University of Ferrara; L. Terslev, MD, PhD, COPECARE; K.J. Warrington, MD, Mayo Clinic; B. Dasgupta, MBBS, MD, FRCP, Southend University Hospital, NHS Foundation Trust and Anglia Ruskin University; W.A. Schmidt, MD, Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch. valentin.s.schaefer@hotmail.de. 3. From the University Hospital Bonn III, Medical Clinic, Department of Oncology, Hematology and Rheumatology, Bonn; Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch, Berlin; Asklepios Medical Center, Bad Abbach, Germany; Hospital of Southwest Denmark, Esbjerg; Diagnostic Centre Region Hospital Silkeborg, Silkeborg; Odense University Hospital, Odense; Copenhagen Center for Arthritis Research (COPECARE), Glostrup, Denmark; Medical University Graz, Graz; Medical University Innsbruck, Innsbruck, Austria; Hospital of Bruneck, Bruneck; Università degli Studi di Torino, Turin; Epidemiology Unit - Italian Society for Rheumatology (SIR), Milan; Arcispedale Santa Maria Nuova, Reggio Emilia; University of Ferrara, Italy; MC Groep Hospitals, Lelystad; Leiden University Medical Center, the Netherlands; Hôpital Ambroise Paré, Boulogne-Billancourt, France; University Hospital La Paz, Madrid, Spain; Martina Hansens Hospital, Bærum, Oslo, Norway; University Medical Centre Ljubljana, Ljubljana, Slovenia; University of California at Los Angeles, Los Angeles, California; Mayo Clinic, Rochester, Minnesota, USA; Pomeranian Medical University, Szczecin, Poland; Norfolk and Norwich University Hospital, Norwich; Southend University Hospital, UK National Health Service (NHS) Foundation Trust and Anglia Ruskin University, Westcliff, UK; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon; Rheumatology Department, Hospital de Santa Maria - CHLN, Lisbon, Portugal. 4. V.S. Schäfer, MD, University Hospital Bonn III, Medical Clinic, Department of Oncology, Hematology and Rheumatology, and Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch; S. Chrysidis, MD, Hospital of Southwest Denmark; C. Dejaco, MD, PhD, Medical University Graz, and Hospital of Bruneck; C. Duftner, MD, PhD, Medical University Innsbruck; A. Iagnocco, MD, Università degli Studi di Torino; G.A. Bruyn, MD, PhD, MC Groep Hospitals; G. Carrara, MSc, Epidemiology Unit - SIR; M.A. D'Agostino, MD, PhD, Hôpital Ambroise Paré; E. De Miguel, MD, University Hospital La Paz; A.P. Diamantopoulos, MD, PhD, MPH, Martina Hansens Hospital; U. Fredberg, MD, PhD, Diagnostic Centre Region Hospital Silkeborg, and Odense University Hospital; W. Hartung, MD, Asklepios Medical Center; A. Hocevar, MD, MSc, University Medical Centre Ljubljana; A. Juche, MD, Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch; T.A. Kermani, MD, University of California at Los Angeles; M.J. Koster, MD, Mayo Clinic; T. Lorenzen, MD, Diagnostic Centre Region Hospital Silkeborg; P. Macchioni, MD, Arcispedale Santa Maria Nuova; M. Milchert, MD, PhD, Pomeranian Medical University; U.M. Døhn, MD, PhD, COPECARE; C. Mukhtyar, MBBS, MSc, MD, Norfolk and Norwich University Hospital; C. Ponte, MD, Rheumatology Research Unit, Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, and Rheumatology Department, Hospital de Santa Maria - CHLN; S. Ramiro, MD, MSc, PhD, Leiden University Medical Center; C.A. Scirè, MD, PhD, Epidemiology Unit - SIR, and University of Ferrara; L. Terslev, MD, PhD, COPECARE; K.J. Warrington, MD, Mayo Clinic; B. Dasgupta, MBBS, MD, FRCP, Southend University Hospital, NHS Foundation Trust and Anglia Ruskin University; W.A. Schmidt, MD, Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch.
Abstract
OBJECTIVE: To test the reliability of Outcome Measures in Rheumatology Clinical Trials (OMERACT) consensus-based ultrasound definitions for normal and vasculitic temporal and axillary arteries in patients with giant cell arteritis (GCA) and in controls. METHODS: A preliminary 1-day meeting and a full 3-day meeting fulfilling OMERACT Ultrasound Group guidelines were held. Temporal and axillary arteries were examined at 2 timepoints by 12 sonographers on 4 patients with GCA and 2 controls. The aim was to test inter- and intrareader reliability for normal findings, halo sign, and compression sign. In both meetings, patients had established GCA. Pathology was more recent in the full meeting, which was preceded by 6 h of training. Scanning time was 15-20 min instead of 10-13 min. RESULTS: In the preliminary exercise, interreader reliabilities were fair to moderate for the overall diagnosis of GCA (Light κ 0.29-0.51), and poor to fair for identifying vasculitis in the respective anatomical segments (Light κ 0.02-0.46). Intrareader reliabilities were moderate (Cohen κ 0.32-0.64). In the main exercise, interreader reliability was good to excellent (Light κ 0.76-0.86) for the overall diagnosis of GCA, and moderate to good (Light κ 0.46-0.71) for identifying vasculitis in the respective anatomical segments. Intrareader reliability was excellent for diagnosis of GCA (Cohen κ 0.91) and good (Cohen κ 0.71-0.80) for the anatomical segments. CONCLUSION: OMERACT-derived definitions of halo and compression signs of temporal and axillary arteries are reliable in recent-onset GCA if experienced sonographers (> 300 examinations) have 15-20 min for a standardized examination with prior training and apply > 15 MHz probes.
OBJECTIVE: To test the reliability of Outcome Measures in Rheumatology Clinical Trials (OMERACT) consensus-based ultrasound definitions for normal and vasculitic temporal and axillary arteries in patients with giant cell arteritis (GCA) and in controls. METHODS: A preliminary 1-day meeting and a full 3-day meeting fulfilling OMERACT Ultrasound Group guidelines were held. Temporal and axillary arteries were examined at 2 timepoints by 12 sonographers on 4 patients with GCA and 2 controls. The aim was to test inter- and intrareader reliability for normal findings, halo sign, and compression sign. In both meetings, patients had established GCA. Pathology was more recent in the full meeting, which was preceded by 6 h of training. Scanning time was 15-20 min instead of 10-13 min. RESULTS: In the preliminary exercise, interreader reliabilities were fair to moderate for the overall diagnosis of GCA (Light κ 0.29-0.51), and poor to fair for identifying vasculitis in the respective anatomical segments (Light κ 0.02-0.46). Intrareader reliabilities were moderate (Cohen κ 0.32-0.64). In the main exercise, interreader reliability was good to excellent (Light κ 0.76-0.86) for the overall diagnosis of GCA, and moderate to good (Light κ 0.46-0.71) for identifying vasculitis in the respective anatomical segments. Intrareader reliability was excellent for diagnosis of GCA (Cohen κ 0.91) and good (Cohen κ 0.71-0.80) for the anatomical segments. CONCLUSION: OMERACT-derived definitions of halo and compression signs of temporal and axillary arteries are reliable in recent-onset GCA if experienced sonographers (> 300 examinations) have 15-20 min for a standardized examination with prior training and apply > 15 MHz probes.
Authors: Alwin Sebastian; Kornelis S M van der Geest; Fiona Coath; Prisca Gondo; Abdul Kayani; Craig Mackerness; Bernard Hadebe; Sue Innes; Jo Jackson; Bhaskar Dasgupta Journal: BMC Rheumatol Date: 2020-08-18
Authors: Lara Clarissa Burg; Wolfgang Andreas Schmidt; Peter Brossart; Katharina Isabell Reinking; Franziskus Maria Schützeichel; Robert Patrick Finger; Valentin Sebastian Schäfer Journal: BMC Med Imaging Date: 2021-03-20 Impact factor: 1.930
Authors: Alwin Sebastian; Fiona Coath; Sue Innes; Jo Jackson; Kornelis S M van der Geest; Bhaskar Dasgupta Journal: Rheumatol Adv Pract Date: 2021-08-19